Literature DB >> 19603000

Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Jenny A Greig1, Suzanne Mk Buckley, Simon N Waddington, Alan L Parker, David Bhella, Rebecca Pink, Ahad A Rahim, Takashi Morita, Stuart A Nicklin, John H McVey, Andrew H Baker.   

Abstract

The binding of coagulation factor X (FX) to the hexon of adenovirus (Ad) 5 is pivotal for hepatocyte transduction. However, vectors based on Ad35, a subspecies B Ad, are in development for cancer gene therapy, as Ad35 utilizes CD46 (which is upregulated in many cancers) for transduction. We investigated whether interaction of Ad35 with FX influenced vector tropism using Ad5, Ad35, and Ad5/Ad35 chimeras: Ad5/fiber(f)35, Ad5/penton(p)35/f35, and Ad35/f5. Surface plasmon resonance (SPR) revealed that Ad35 and Ad35/f5 bound FX with approximately tenfold lower affinities than Ad5 hexon-containing viruses, and electron cryomicroscopy (cryo-EM) demonstrated a direct Ad35 hexon:FX interaction. The presence of physiological levels of FX significantly inhibited transduction of vectors containing Ad35 fibers (Ad5/f35, Ad5/p35/f35, and Ad35) in CD46-positive cells. Vectors were intravenously administered to CD46 transgenic mice in the presence and absence of FX-binding protein (X-bp), resulting in reduced liver accumulation for all vectors. Moreover, Ad5/f35 and Ad5/p35/f35 efficiently accumulated in the lung, whereas Ad5 demonstrated poor lung targeting. Additionally, X-bp significantly reduced lung genome accumulation for Ad5/f35 and Ad5/p35/f35, whereas Ad35 was significantly enhanced. In summary, vectors based on the full Ad35 serotype will be useful vectors for selective gene transfer via CD46 due to a weaker FX interaction compared to Ad5.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19603000      PMCID: PMC2835023          DOI: 10.1038/mt.2009.152

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

3.  The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Vladimir Ternovoi; Anuj Gaggar; Helen Gharwan; André Lieber
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue.

Authors:  K P Murray; S Mathure; R Kaul; S Khan; L F Carson; L B Twiggs; M G Martens; A Kaul
Journal:  Gynecol Oncol       Date:  2000-02       Impact factor: 5.482

6.  Improved adenovirus vectors for infection of cardiovascular tissues.

Authors:  M J Havenga; A A Lemckert; J M Grimbergen; R Vogels; L G Huisman; D Valerio; A Bout; P H Quax
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

8.  Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm.

Authors:  Naokazu Inoue; Masahito Ikawa; Tomoko Nakanishi; Misako Matsumoto; Midori Nomura; Tsukasa Seya; Masaru Okabe
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

Authors:  Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

10.  Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.

Authors:  Alan L Parker; John H McVey; Jessica H Doctor; Oscar Lopez-Franco; Simon N Waddington; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

View more
  22 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

2.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 3.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

Review 4.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

Review 5.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

6.  Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Authors:  Jeffrey E Teigler; M Justin Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 7.  Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.

Authors:  Gabor M Rubanyi
Journal:  Mol Ther       Date:  2013-02-12       Impact factor: 11.454

8.  Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.

Authors:  Jeffrey E Teigler; Pablo Penaloza-MacMaster; Rebecca Obeng; Nicholas M Provine; Rafael A Larocca; Erica N Borducchi; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2014-06-18

9.  Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44⁺ gastric cancer cells via attenuating Wnt signaling.

Authors:  Bin Wang; Jia Liu; Lei Na Ma; Hua Liang Xiao; Ya Zhou Wang; Yan Li; Zhe Wang; Linli Fan; Chunhui Lan; Min Yang; Lu Hu; Yanlin Wei; Xiu Wu Bian; Dongfeng Chen; Jun Wang
Journal:  J Gastroenterol       Date:  2012-11-28       Impact factor: 7.527

10.  The CD46-Jagged1 interaction is critical for human TH1 immunity.

Authors:  Gaëlle Le Friec; Devon Sheppard; Pat Whiteman; Christian M Karsten; Salley Al-Tilib Shamoun; Adam Laing; Laurence Bugeon; Margaret J Dallman; Teresa Melchionna; Chandramouli Chillakuri; Richard A Smith; Christian Drouet; Lionel Couzi; Veronique Fremeaux-Bacchi; Jörg Köhl; Simon N Waddington; James M McDonnell; Alastair Baker; Penny A Handford; Susan M Lea; Claudia Kemper
Journal:  Nat Immunol       Date:  2012-10-21       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.